Today: April 27, 2018, 10:46 am
  
Business

Novodiag® Bacterial GE+, a New Diagnostic Test for on-Demand Detection of Bacterial Pathogens

PR-Inside.com: 2018-04-17 07:01:02

Novodiag® Bacterial GE+, a New Diagnostic Test for on-Demand Detection of Bacterial Pathogens

Mobidiag
Dorothee Allard, +33 1 55 25 17 13
marketing@mobidiag.com

Mobidiag, a Finnish molecular diagnostics company, today announced the launch of Novodiag® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currently used culture methods.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180416005

Novodiag® Bacterial GE+, molecular diagnostic test for on-demand detection of bacterial pathogens (P ...

Novodiag® Bacterial GE+, molecular diagnostic test for on-demand detection of bacterial pathogens (Photo: Mobidiag)

“The new Novodiag Bacterial GE+ cartridge can identify dozens of targets, including the majority of bacteria causing diarrhea. Thanks to its simplified and optimized workflow, our fully automated Novodiag solution can support early decision making prior to any treatment delivery and improve patient care by managing infections accordingly” explains Tuomas Tenkanen. “We are very proud to now offer the first syndromic test compatible with our Novodiag system. Our ambition is to make accessible one of the most relevant range of test panels. We are currently working on extending our product line and address among others the detection of antibiotic resistances to improve the correct use of antibiotics”.

Novodiag® Bacterial GE+ test is now available directly through Mobidiag and local distributors. For more information, visit our product page.

About Novodiag® (CE-IVD)
The Novodiag solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour. Combining qPCR and microarray technologies, Novodiag offers an all in one solution for on-demand targeted and syndromic testing.
This molecular diagnostic solution offers an easy to use and cost-efficient method, with very limited hands-on-time and without the need for much technical expertise. Novodiag is suitable for all test volumes and on demand testing for clinical laboratories.
Learn more about Novodiag.

About Mobidiag Ltd.
Established in 2000, Mobidiag develops and commercializes innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D center in France and subsidiaries in UK and Sweden.
Combining Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line of products for fast, reliable and cost-efficient diagnostics for infectious diseases and antibiotic resistances. Mobidiag is able to cover all laboratories requirements no matter their size, throughput and centralized/ decentralized organization.
To learn more, visit mobidiag.com

Press Information


Published by
Hossam Abdel-Kader
+43 1 9582319
e-mail
www.pr-inside.com/



# 640 Words
Related Articles
More From The Author
Collab Winners Are ‘Building a Long-Term Relationship’ [..]
Insurtech start-ups competing to win a US$100,000 contract to develop and pilot solutions with MetLife EMEA can look forward to [..]
CFRA to Provide Independent Equity Research to [..]
CFRA : SGX-listed companies that choose CFRA to produce independent research can utilize these reports directly with investors while [..]
Hong Kong Highways Department Selects Telensa for [..]
Telensa : This press release features multimedia. View the full release here. Yuen Long Skyline (By WiNG - Own work, [..]
AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination [..]
Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 greater than or equal to 25% and less than [..]
Novavax Announces Closing of Public Offering
GAITHERSBURG, Md., April 16, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed [..]
 
More From Business
Kiwis Are Still Not Taking Advantage of [..]
A recent opinion piece in Stuff speculated about the reasons why Kiwis have not been rushing to sign up to [..]
More Kiwis Homeowners Choose Open Floor Plan [..]
In New Zealand, the open floor plan is a common sight. Most common areas, especially the living room, dining room, [..]
Buy Single Use Laparoscopic Instruments from Endovision
Specialised Surgical company Endovision has a range of laparoscopic instruments available for sale through their website. The [..]
JCBI and Far Eastern Bank sign a [..]
Vladivostok, Russia & Tokyo, Japan, Apr 26, 2018 - (ACN Newswire) - JCB International Co., Ltd. (JCBI), the international operations [..]
Trillium Appoints Global Director of Engineering
TOKYO, Apr 20, 2018 - (ACN Newswire) - Trillium Secure, Inc., the global leader in delivering cyber security as a [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.